Compare CTRN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTRN | AVIR |
|---|---|---|
| Founded | 1946 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.5M | 434.5M |
| IPO Year | 2005 | 2020 |
| Metric | CTRN | AVIR |
|---|---|---|
| Price | $44.60 | $5.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $52.00 | $10.00 |
| AVG Volume (30 Days) | 76.3K | ★ 225.6K |
| Earning Date | 06-02-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.14 | 3.00 |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $819,962,000.00 | $351,367,000.00 |
| Revenue This Year | $8.81 | N/A |
| Revenue Next Year | $8.35 | N/A |
| P/E Ratio | $74.01 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $23.60 | $2.46 |
| 52 Week High | $56.78 | $6.45 |
| Indicator | CTRN | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 41.87 | 43.96 |
| Support Level | $42.06 | $5.13 |
| Resistance Level | $48.59 | $6.37 |
| Average True Range (ATR) | 2.66 | 0.23 |
| MACD | -0.48 | -0.02 |
| Stochastic Oscillator | 10.38 | 24.58 |
Citi Trends Inc is a differentiated off-price value retailer known for trendy fashions, great brands and amazing prices. It is the off-price retailer specifically focused on Black customers, delivering the styles, brands, and trends at amazing prices that resonate with its primary and secondary customers. Its product offering is Women's, Men's and Children's apparel, family footwear, accessories and products for the home, with a three-tiered mix of product. At the opening price point, the company offers value-focused basics for its budget-conscious customers.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.